» Articles » PMID: 35501873

Acquired Hemophilia A in the Setting of Dual Anticoagulation Therapy and Lupus Anticoagulant: a Case Report

Overview
Journal J Med Case Rep
Publisher Biomed Central
Specialty General Medicine
Date 2022 May 3
PMID 35501873
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acquired hemophilia A is a disorder caused by autoantibodies against coagulation factor VIII that may present with severe bleeding. We report a rare case of acquired hemophilia A presenting with coexisting lupus anticoagulant.

Case Presentation: An 81-year-old Caucasian female presented with large ecchymoses over the torso and extremities in the setting of an enoxaparin bridge to warfarin. Anticoagulation was held, but she continued to develop bruises with significant anemia and prolonged coagulation studies that failed to correct with mixing. Workup revealed factor VIII activity < 1% and a positive lupus anticoagulant. Initial testing for a factor VIII inhibitor was confounded by the presence of lupus anticoagulant, requiring a chromogenic Bethesda assay to confirm the presence of the inhibitor, establishing the diagnosis of acquired hemophilia A. The patient was initially treated with oral prednisone 80 mg daily and factor VIII inhibitor bypassing activity 25 units/kg twice daily before transitioning to susoctocog alfa 50 units/kg twice daily after placement of a tunneled line for outpatient rituximab infusions. On discharge, the patient's ecchymoses were resolving and factor VIII levels improved. Following completion of rituximab therapy, the patient's factor VIII activity normalized and factor VIII inhibitor was suppressed.

Conclusions: Diagnosis of acquired hemophilia A can be confounded by other causes of abnormal coagulation studies and may require specialized testing, such as a chromogenic Bethesda assay, to confirm the presence of a factor VIII inhibitor.

Citing Articles

A Rare Case of Acquired Factor VIII Inhibition in an Elderly Female.

Niazi B, Millhouse P, Jarri A, Al-Awwa A, Gupta B, Perrella B J Community Hosp Intern Med Perspect. 2024; 14(2):113-116.

PMID: 38966518 PMC: 11221447. DOI: 10.55729/2000-9666.1224.

References
1.
Miller C, Platt S, Rice A, Kelly F, Soucie J . Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. J Thromb Haemost. 2012; 10(6):1055-61. PMC: 4477703. DOI: 10.1111/j.1538-7836.2012.04705.x. View

2.
Saxena R, Dhot P, Saraya A, Singh H, Malhotra O . Simultaneous occurrence of factor VIIIC inhibitor and lupus anticoagulant. Am J Hematol. 1993; 42(2):232-3. DOI: 10.1002/ajh.2830420221. View

3.
Gupta D, Chatterjee T, Sharma A, Ganguli P, Das S, Sharma S . Rare case of acquired haemophilia and lupus anticoagulant. Indian J Hematol Blood Transfus. 2014; 30(3):197-200. PMC: 4115089. DOI: 10.1007/s12288-012-0204-5. View

4.
Chandler W, Ferrell C, Lee J, Tun T, Kha H . Comparison of three methods for measuring factor VIII levels in plasma. Am J Clin Pathol. 2003; 120(1):34-9. DOI: 10.1309/C8T8-YNB4-G3W4-5PRF. View

5.
Witt D . What to do after the bleed: resuming anticoagulation after major bleeding. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):620-624. PMC: 6142471. DOI: 10.1182/asheducation-2016.1.620. View